145 related articles for article (PubMed ID: 15254410)
1. 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
Dwarakanath BS; Khaitan D; Ravindranath T
Cancer Biol Ther; 2004 Sep; 3(9):864-70. PubMed ID: 15254410
[TBL] [Abstract][Full Text] [Related]
2. The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.
Gupta S; Mathur R; Dwarakanath BS
Cancer Biol Ther; 2005 Jan; 4(1):87-94. PubMed ID: 15711125
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines.
Dwarkanath BS; Zolzer F; Chandana S; Bauch T; Adhikari JS; Muller WU; Streffer C; Jain V
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1051-61. PubMed ID: 11429233
[TBL] [Abstract][Full Text] [Related]
4. Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in cancer cells.
Dwarakanath BS; Adhikari JS; Jain V
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1125-33. PubMed ID: 10192364
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells.
Varshney R; Dwarakanath B; Jain V
Int J Radiat Biol; 2005 May; 81(5):397-408. PubMed ID: 16076755
[TBL] [Abstract][Full Text] [Related]
6. Role of topoisomerases in cytotoxicity induced by DNA ligand Hoechst-33342 and UV-C in a glioma cell line.
Singh S; Dwarakanath BS; Lazar Mathew T
Indian J Exp Biol; 2005 Apr; 43(4):313-23. PubMed ID: 15875714
[TBL] [Abstract][Full Text] [Related]
7. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of radionuclide induced cytotoxicity by 2-deoxy-D-glucose in human tumor cell lines.
Shrivastava V; Mishra AK; Dwarakanath BS; Ravindranath T
J Cancer Res Ther; 2006; 2(2):57-64. PubMed ID: 17998676
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in the radiosensitizing effects of the DNA ligand hoechst-33342 in human tumor cell lines.
Adhikari JS; Khaitan D; Arya MB; Dwarakanath BS
J Cancer Res Ther; 2005; 1(3):151-61. PubMed ID: 17998647
[TBL] [Abstract][Full Text] [Related]
10. Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line.
Khaitan D; Chandna S; Arya MB; Dwarakanath BS
Cancer Biol Ther; 2006 Sep; 5(9):1142-51. PubMed ID: 16855378
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
12. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
13. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
14. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
[TBL] [Abstract][Full Text] [Related]
15. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
16. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
17. Differential modification of radiation damage in 5-bromo-2-deoxy-uridine sensitized human glioma cells and PHA-stimulated peripheral leukocytes by 2-deoxy-D-glucose.
Kalia VK; Devi NK
Indian J Exp Biol; 1994 Sep; 32(9):637-42. PubMed ID: 7814043
[TBL] [Abstract][Full Text] [Related]
18. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy.
Kalia VK; Prabhakara S; Narayanan V
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S57-60. PubMed ID: 20009297
[TBL] [Abstract][Full Text] [Related]
19. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Ng CE; Bussey AM; Raaphorst GP
Int J Radiat Biol; 1994 Jul; 66(1):49-57. PubMed ID: 8027612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
